OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/NTRK2
Lung Cancer — Non-Small Cell (NSCLC)NTRK2 Clinical Trials
NTRK2 fusions are rare in NSCLC and qualify patients for tumor-agnostic treatment with larotrectinib or entrectinib under their FDA approvals covering all TrkB-fusion-positive solid tumors. These inhibitors demonstrate durable responses across tumor types. Trials explore second-generation NTRK inhibitors and combination strategies for resistance.
Top recruiting NTRK2 Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and US site count.
See all trials matched to your profile →Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC
Shouyao Holdings (Beijing) Co. LTD
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Sinocelltech Ltd.
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
Guangdong Provincial People's Hospital
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Genentech, Inc.
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Memorial Sloan Kettering Cancer Center
More NTRK2 Lung Cancer — Non-Small Cell (NSCLC) trials
5 international trials (no US sites)
FDA-approved therapies for NTRK2 Lung Cancer — Non-Small Cell (NSCLC)
Approved agents for this molecular target. Indication labels specify the approved patient population — some approvals apply to specific variants only.